# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Colleen Kusy initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating and announces P...
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of ...
Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising ...
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NA...
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to prec...
Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised t...
Mizuho analyst Salim Syed initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announces Price Tar...
Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the d...